The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: First in Human Dose Escalation of M3258 as a Single Agent and Expansion Study of M3258 in Combination With Dexamethasone
Official Title: A Phase I Open Label First in Human Dose Escalation of the Immunoproteasome Inhibitor M3258 as a Single Agent and Expansion Study of M3258 in Combination With Dexamethasone in Participants With Relapsed Refractory Multiple Myeloma
Study ID: NCT04075721
Brief Summary: The purpose of this study was to determine the safety, tolerability, pharmacokinetics, pharmacodynamics and early efficacy signs of M3258 as a single agent and co-administered with dexamethasone in participants with Relapsed Refractory Multiple Myeloma (RRMM).
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Colorado Blood Cancer Institute, Denver, Colorado, United States
Georgetown University Medical Center- Research Parent, Washington, District of Columbia, United States
Hackensack University Medical Center, Hackensack, New Jersey, United States
Sarah Cannon Research Institute, Nashville, Tennessee, United States
Centre Hospitalier Regional Universitaire de Lille, Lille, , France
CHU de Nantes, Nantes, , France
CHU de Poitiers, Vauvert, , France
Name: Medical Responsible
Affiliation: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Role: STUDY_DIRECTOR